DeepMed Research

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Phase 2

Recruiting

Conditions: ESCC
Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: Ivonescimab combined with albumin paclitaxel and cisplatin

First Posted Date: 2024-07-05

Last Posted Date: 2025-01-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06489197

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Not Applicable

Recruiting

Conditions: Liver Malignant Tumors
Hepatocellular Carcinoma Non-resectable
Liver Metastases
Cholangiocarcinoma Non-resectable

Interventions: Procedure: TACE with ICI

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT06487663

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 109

Registration Number: NCT06483386

Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure.

Not Applicable

Completed

Conditions: Abdominal Cancer
Thoracic Cancer

Interventions: Procedure: CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions
Procedure: Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-05

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 166

Registration Number: NCT06484764

Locations: 🇨🇳
First Clinical Affiliation of Guangzhou Medical University, Guangzhou, China
🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
🇨🇳
Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Phase 2

Not yet recruiting

Conditions: FL

Interventions: Drug: Zanubrutinib
Drug: Obinutuzumab
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06474481

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Phase 2

Recruiting

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Gemcitabine
Drug: Nab-Paclitaxel

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-04

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06472037

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Phase 2

Recruiting

Conditions: MCL

Interventions: Drug: BGB-11417
Drug: BGB-3111
Drug: CD20

First Posted Date: 2024-06-18

Last Posted Date: 2025-05-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06463691

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions: Drug: Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel
Drug: Sintilimab + S-1 plus nab-paclitaxel

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 158

Registration Number: NCT06454435

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Adebrelimab (SHR-1316)
Metastatic Pancreatic Cancer
Decitabine

Interventions: Drug: Adebrelimab;decitabine;

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-28

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT06454448

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

Phase 2

Not yet recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy
Drug: Induction immunochemotherapy followed by concurrent chemoradiotherapy

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT06452602

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy